Genetic Technologies Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
May 13 2021 - 9:01AM
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”,
“GTG”), a diversified Genomics and AI driven preventative health
business, today announced an interview with Simon Morriss, CEO,
will air on The RedChip Money Report® on the Bloomberg Network in
the U.S. on Saturday, May 15th, at 7 p.m. local time in 73M homes
across the United States.
In the exclusive interview, Mr. Morriss
discusses the Company’s upcoming milestones, updates on the
company’s lead risk assessment products, GeneType for Breast
Cancer, for non-hereditary breast cancer and GeneType for
Colorectal Cancer, as well as their Covid19 Risk Assessment test.
Mr. Morriss also discusses the company’s developing pipeline of
risk assessment products and commercialization plans.
To view the interview segment, please visit:
https://youtu.be/-o-2YWJ7FyU
“The RedChip Money Report" delivers insightful
commentary on small-cap investing, interviews with Wall Street
analysts, financial book reviews, as well as featured interviews
with executives of public companies.
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq:
GENE) is a diversified molecular diagnostics company. GTG offers
cancer predictive testing and assessment tools to help physicians
proactively manage patient health. The Company’s lead products
GeneType for Breast Cancer for non-hereditary breast cancer and
GeneType for Colorectal Cancer are clinically validated risk
assessment tests and are first in class. Genetic Technologies is
developing a pipeline of risk assessment products.
For more information, please visit
www.gtglabs.com
Investor Relations (AUS) |
Investor Relations and Media (US) |
Stephanie Ottens |
Dave Gentry |
Market Eye |
1 800 RED CHIP (733 2447) |
M: +61 434 405 400 |
Cell: 407 491 4498 |
E: stephanie.ottens@marketeye.com.au |
E: dave@redchip.com |
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Apr 2023 to Apr 2024